Morepen Laboratories Limited announced the launch of 'Empamore' on 17 Mar 25, a new treatment for Type 2 Diabetes Mellitus (T2DM), Heart Failure with Reduced Ejection Fraction (HFrEF), and Chronic Kidney Disease (CKD). Manufactured in USFDA-approved facilities, 'Empamore' aims to provide affordable, high-quality diabetes care, priced nearly 90% lower than existing brands, approximately 90% lower cost. The product range includes:

• Empagliflozin (Empamore 10mg/25mg)
• Empagliflozin 12.5mg with Metformin 500/1000mg (Empamore M 500/1000mg)

Morepen emphasizes its 40-year legacy in diabetes care, noting it has already installed 12.33 million glucometers and sold 1.65 billion blood glucose strips. 'Empamore' will be available nationwide and is packaged in convenient perforated strips for better patient adherence. Morepen Labs, established in 1984, has a global presence spanning 82 countries.